Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT ID: NCT02179086
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
606 participants
INTERVENTIONAL
2014-12-04
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To determine if dose-escalated and -intensified photon IMRT or proton beam therapy (using a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and adjuvant temozolomide improves overall survival, as compared to standard-dose photon irradiation with concomitant and adjuvant temozolomide.
SECONDARY OBJECTIVES:
I. To indirectly compare dose-escalated and -intensified photon IMRT to dose-escalated and -intensified proton beam therapy in terms of overall survival.
II. To indirectly compare and record toxicities of dose-escalated and -intensified photon IMRT versus dose-escalated and -intensified proton beam therapy and directly compare the toxicities of these approaches versus standard-dose photon irradiation on the backbone of concomitant and adjuvant temozolomide.
III. To determine if dose-escalated and -intensified IMRT or proton beam therapy (using a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and adjuvant temozolomide improves perceived cognitive symptom severity, as compared to standard-dose photon irradiation with concomitant and adjuvant temozolomide.
IV. To determine if dose-escalated and -intensified photon IMRT or proton beam therapy (using a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and adjuvant temozolomide improves neurocognitive function, as compared to standard-dose photon irradiation with concomitant and adjuvant temozolomide.
V. To indirectly determine if dose-escalated and -intensified proton beam therapy with concomitant and adjuvant temozolomide improves perceived cognitive symptom severity, as compared to dose-escalated and -intensified photon IMRT, and to directly compare symptom burden with these approaches versus standard-dose photon irradiation on the backbone of concomitant and adjuvant temozolomide.
VI. To indirectly determine if dose-escalated and -intensified proton beam therapy with concomitant and adjuvant temozolomide improves neurocognitive function, as compared to dose-escalated and -intensified photon IMRT, and to directly compare neurocognitive function with these approaches versus standard-dose photon irradiation on the backbone of concomitant and adjuvant temozolomide.
EXPLORATORY OBJECTIVES:
I. Tissue banking for future translational science projects that will be determined based on the state of the science at the time the primary endpoint is reported and will be submitted to National Cancer Institute (NCI) for review and approval.
II. To prospectively compare CD4 lymphopenia between dose-escalated and intensified proton beam therapy, dose-escalated and -intensified photon IMRT, and standard-dose photon irradiation and determine whether CD4 lymphopenia impacts overall survival.
III. To explore the most appropriate and clinically relevant technological parameters to ensure quality and effectiveness throughout radiation therapy processes, including imaging, simulation, patient immobilization, target and critical structure definition, treatment planning, image guidance and delivery.
IIIa. To establish feasibility and clinical relevancy of quality assurance guidelines.
IIIb. To evaluate efficacy of quality assurance tools. IV. To explore the most appropriate and clinically relevant advanced and standard magnetic resonance imaging (MRI) imaging parameters.
IVa. To evaluate the feasibility of differentiating pseudo-progression and true progression in a multi institutional setting using magnetic resonance (MR) diffusion and perfusion imaging.
IVb. To evaluate for early, imaging biomarkers of response and overall survival.
OUTLINE: Patients are assigned to 1 of 2 groups depending on enrolling institution. Within each group, patients will be randomized 1:2 in favor of the experimental arms.
GROUP I (PHOTON IMRT CENTERS): Patients are randomized to 1 of 2 treatment arms.
ARM A1: Patients undergo standard-dose photon irradiation using 3-dimensional conformal radiation therapy (3D-CRT) or IMRT once daily (QD), 5 days a week for 23 fractions plus a boost of 7 additional fractions.
ARM B: Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.
GROUP II (PROTON CENTERS): Patients are randomized to 1 of 2 treatment arms.
ARM A2: Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.
ARM C: Patients undergo dose-escalated and -intensified proton beam radiation therapy QD, 5 days a week for a total of 30 fractions.
In all treatment arms, patients receive temozolomide orally (PO) QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, every 4 months for 1 year, and then every 6 months thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A1 (control)
Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT QD, 5 days a week for 23 fractions plus a boost of 7 additional fractions.
In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3-Dimensional Conformal Radiation Therapy
Undergo standard-dose 3D-CRT
Intensity-Modulated Radiation Therapy
Undergo standard-dose IMRT
Laboratory Biomarker Analysis
Correlative studies
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Temozolomide
Given PO
Arm A2 (control)
Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.
In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3-Dimensional Conformal Radiation Therapy
Undergo standard-dose 3D-CRT
Intensity-Modulated Radiation Therapy
Undergo standard-dose IMRT
Laboratory Biomarker Analysis
Correlative studies
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Temozolomide
Given PO
Arm B (photon IMRT)
Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.
In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Intensity-Modulated Radiation Therapy
Undergo dose-escalated and -intensified photon IMRT
Laboratory Biomarker Analysis
Correlative studies
Photon Beam Radiation Therapy
Undergo dose-escalated and -intensified photon IMRT
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Temozolomide
Given PO
Arm C (proton beam radiation therapy)
Patients undergo dose-escalated and -intensified proton beam therapy QD, 5 days a week for a total of 30 fractions.
In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis
Correlative studies
Proton Beam Radiation Therapy
Undergo dose-escalated and -intensified proton beam radiation therapy
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Temozolomide
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3-Dimensional Conformal Radiation Therapy
Undergo standard-dose 3D-CRT
Intensity-Modulated Radiation Therapy
Undergo standard-dose IMRT
Intensity-Modulated Radiation Therapy
Undergo dose-escalated and -intensified photon IMRT
Laboratory Biomarker Analysis
Correlative studies
Photon Beam Radiation Therapy
Undergo dose-escalated and -intensified photon IMRT
Proton Beam Radiation Therapy
Undergo dose-escalated and -intensified proton beam radiation therapy
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Temozolomide
Given PO
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnostic contrast-enhanced MRI (no other scan type allowed) of the brain must be performed postoperatively; the residual enhancing tumor and/or resection cavity must have a maximal diameter of 5 cm or less; the tumor diameter will be the greatest diameter as measured on the contrast-enhanced postoperative MRI and will include residual disease and/or the postoperative surgical cavity as appropriate
* The postoperative brain MRI should be obtained within 72 hours of resection; if it is not obtained within 72 hours post-resection, then an MRI obtained 2 weeks or longer after surgery is required and can be utilized to ensure maximal diameter of residual tumor and/or resection cavity is 5 cm or less
* For cases where a gross total resection of enhancing tumor is performed, but postoperative surgical cavity is NOT identifiable, the patient will be excluded from the trial
* Tumor tissue must be available for submission for central pathology review
* Timing requirements:
* If MGMT has been assessed locally by LabCorps or MD Anderson Cancer Center Molecular Diagnostics Lab (MDACC-MDL):
* Tissue for central pathology review and central MGMT assessment and the official LabCorps or MDACC-MDL MGMT result must be received by the NRG Oncology Biospecimen Bank on or before postoperative calendar day 40
* The site's local MGMT report from LabCorp or MDACC-MDL will then be used to stratify the patient; a post-stratification MGMT central review will be performed, but step 2 registration and protocol treatment can proceed without central review of MGMT
* Patients whose tissue for central pathology review and official LabCorps or MDACC-MDL MGMT result cannot be received by NRG Oncology Biospecimen Bank on or before 40 calendar days after surgery may NOT enroll on this trial, as central pathology review and stratification will not be complete in time for the patient to start treatment within 49 calendar days following surgery
* If MGMT has not been assessed locally by LabCorps or MDACC-MDL:
* Tissue for central pathology review and central MGMT assessment must be received by the NRG Oncology Biospecimen Bank on or before postoperative calendar day 30
* Central MGMT analysis will be performed at MDACC-MDL and used for patient stratification; results will be conveyed to NRG Oncology within 10 business days of receipt of the tissue
* Patients who have not had local MGMT assessment by LabCorps or MDACC-MDL and whose tissue for central pathology review cannot be received by NRG Oncology Biospecimen Bank on or before 30 calendar days after surgery may NOT enroll on this trial, as central pathology review and stratification will not be complete in time for the patient to start treatment within 49 calendar days following surgery
* Tissue Requirements:
* Patients must have at least 1 block of tumor tissue; submission of 2 blocks is strongly encouraged to maximize the chances of eligibility; in total, at least 1 cubic centimeter of tissue composed primarily of tumor must be present
* Submission of an accompanying hematoxylin and eosin H\&E slide(s) is MANDATORY
* Diagnosis must be made by surgical excision, either partial or complete; stereotactic biopsy and cavitronic ultrasonic surgical (CUSA) techniques are not allowed
* The tumor must be located in the supratentorial compartment only (any component involving the brain stem or cerebellum is not allowed)
* Patients must provide study-specific informed consent prior to step 1 registration
* PRIOR TO STEP 2 REGISTRATION
* Histologically proven diagnosis of glioblastoma (World Health Organization \[WHO\] grade IV) confirmed by central review prior to step 2 registration
* Tumor tissue that is determined by central pathology review prior to step 2 registration to be of sufficient quantity for central analysis of MGMT status
* History/physical examination within 28 days prior to step 2 registration
* The patient must have recovered from effects of surgery, postoperative infection, and other complications within 28 days prior to step 2 registration
* Documentation of steroid doses within 28 days prior to step 2 registration
* Karnofsky performance status \>= 70 within 28 days prior to step 2 registration
* Age \>= 18
* Complete blood count (CBC)/differential obtained within 28 days prior to step 2 registration
* Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 (obtained within 28 days prior to step 2 registration)
* Platelets \>= 100,000 cells/mm\^3 (obtained within 28 days prior to step 2 registration)
* Hemoglobin \>= 10.0 g/dl (obtained within 28 days prior to step 2 registration) (note: the use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 10.0 g/dl is acceptable)
* Bilirubin =\< 1.5 upper limit of normal (ULN) (within 28 days prior to step 2 registration)
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN (within 28 days prior to step 2 registration)
* Negative serum pregnancy test obtained for females of child-bearing potential within 28 days prior to step 2 registration
* As of Amendment 2, if the registering site is a photon center (registering patients to group I), the patient must agree to participate in the advanced imaging sub-study
Exclusion Criteria
* Recurrent or multifocal malignant gliomas
* Any site of distant disease (for example, drop metastases from the GBM tumor site)
* Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable (except temozolomide)
* Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted
* Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
* Severe, active co-morbidity, defined as follows:
* Unstable angina at step 2 registration
* Transmural myocardial infarction within the last 6 months prior to step 2 registration
* Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of \>= 2 mm using the analysis of an electrocardiogram (EKG) performed within 28 days prior to step 2 registration (Note: EKG to be performed only if clinical suspicion of cardiac issue)
* New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to step 2 registration
* Serious and inadequately controlled arrhythmia at step 2 registration
* Serious or non-healing wound, ulcer or bone fracture or history of abdominal fistula, intra-abdominal abscess requiring major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to step 2 registration, with the exception of the craniotomy for surgical resection
* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 2 registration
* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol
* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 2 registration
* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is because the treatments involved in this protocol may be significantly immunosuppressive with potentially fatal outcomes in patients already immunosuppressed
* Any other severe immunocompromised condition
* Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity
* End-stage renal disease (ie, on dialysis or dialysis has been recommended)
* Any other major medical illnesses or psychiatric treatments that in the investigator's opinion will prevent administration or completion of protocol therapy
* Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
* Patients treated on any other therapeutic clinical protocols within 30 days prior to step 2 registration
* Inability to undergo MRI (e.g., due to safety reasons, such as presence of a pacemaker, or severe claustrophobia)
* Postoperative tumor plus surgical bed size exceeds 5 cm in maximum diameter
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
NRG Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minesh P Mehta
Role: PRINCIPAL_INVESTIGATOR
NRG Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Arizona Oncology Associates-West Orange Grove
Tucson, Arizona, United States
Banner University Medical Center - Tucson
Tucson, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, United States
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California, United States
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, United States
Eden Hospital Medical Center
Castro Valley, California, United States
Fresno Cancer Center
Fresno, California, United States
Marin General Hospital
Greenbrae, California, United States
Loma Linda University Medical Center
Loma Linda, California, United States
Los Angeles General Medical Center
Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Fremont - Rideout Cancer Center
Marysville, California, United States
Memorial Medical Center
Modesto, California, United States
Kaiser Permanente Oakland-Broadway
Oakland, California, United States
Saint Joseph Hospital - Orange
Orange, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States
Palo Alto Medical Foundation Health Care
Palo Alto, California, United States
Pomona Valley Hospital Medical Center
Pomona, California, United States
Kaiser Permanente-Rancho Cordova Cancer Center
Rancho Cordova, California, United States
Rohnert Park Cancer Center
Rohnert Park, California, United States
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, United States
The Permanente Medical Group-Roseville Radiation Oncology
Roseville, California, United States
Sutter Medical Center Sacramento
Sacramento, California, United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
South Sacramento Cancer Center
Sacramento, California, United States
California Pacific Medical Center-Pacific Campus
San Francisco, California, United States
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California, United States
Kaiser Permanente Cancer Treatment Center
South San Francisco, California, United States
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California, United States
John Muir Medical Center-Walnut Creek
Walnut Creek, California, United States
UCHealth Memorial Hospital Central
Colorado Springs, Colorado, United States
Poudre Valley Hospital
Fort Collins, Colorado, United States
Hartford Hospital
Hartford, Connecticut, United States
Boca Raton Regional Hospital
Boca Raton, Florida, United States
University of Florida Health Science Center - Gainesville
Gainesville, Florida, United States
Baptist MD Anderson Cancer Center
Jacksonville, Florida, United States
University of Florida Health Science Center - Jacksonville
Jacksonville, Florida, United States
Baptist Medical Center South
Jacksonville, Florida, United States
Miami Cancer Institute
Miami, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Emory Proton Therapy Center
Atlanta, Georgia, United States
Emory University Hospital Midtown
Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, United States
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
Northwestern University
Chicago, Illinois, United States
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, United States
Rush MD Anderson Cancer Center
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Decatur Memorial Hospital
Decatur, Illinois, United States
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, United States
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, United States
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, United States
Advocate Lutheran General Hospital
Park Ridge, Illinois, United States
OSF Saint Francis Medical Center
Peoria, Illinois, United States
Springfield Memorial Hospital
Springfield, Illinois, United States
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, United States
Radiation Oncology Associates PC
Fort Wayne, Indiana, United States
Parkview Hospital Randallia
Fort Wayne, Indiana, United States
Parkview Regional Medical Center
Fort Wayne, Indiana, United States
IU Health Methodist Hospital
Indianapolis, Indiana, United States
Community Cancer Center East
Indianapolis, Indiana, United States
Community Cancer Center South
Indianapolis, Indiana, United States
Community Cancer Center North
Indianapolis, Indiana, United States
IU Health Ball Memorial Hospital
Muncie, Indiana, United States
Mercy Hospital
Cedar Rapids, Iowa, United States
Iowa Methodist Medical Center
Des Moines, Iowa, United States
University of Kansas Cancer Center
Kansas City, Kansas, United States
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
Norton Hospital Pavilion and Medical Campus
Louisville, Kentucky, United States
Ochsner Medical Center Jefferson
New Orleans, Louisiana, United States
Willis-Knighton Medical and Cancer Center
Shreveport, Louisiana, United States
Maryland Proton Treatment Center
Baltimore, Maryland, United States
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, United States
UM Upper Chesapeake Medical Center
Bel Air, Maryland, United States
Central Maryland Radiation Oncology in Howard County
Columbia, Maryland, United States
UM Baltimore Washington Medical Center/Tate Cancer Center
Glen Burnie, Maryland, United States
Tufts Medical Center
Boston, Massachusetts, United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Boston Medical Center
Boston, Massachusetts, United States
Mass General/North Shore Cancer Center
Danvers, Massachusetts, United States
Lowell General Hospital
Lowell, Massachusetts, United States
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
McLaren Cancer Institute-Bay City
Bay City, Michigan, United States
Corewell Health Dearborn Hospital
Dearborn, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
McLaren Cancer Institute-Flint
Flint, Michigan, United States
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan, United States
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan, United States
West Michigan Cancer Center
Kalamazoo, Michigan, United States
McLaren Cancer Institute-Lapeer Region
Lapeer, Michigan, United States
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, United States
McLaren Cancer Institute-Macomb
Mount Clemens, Michigan, United States
McLaren Cancer Institute-Central Michigan
Mount Pleasant, Michigan, United States
McLaren Cancer Institute-Owosso
Owosso, Michigan, United States
McLaren Cancer Institute-Northern Michigan
Petoskey, Michigan, United States
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, Michigan, United States
Corewell Health William Beaumont University Hospital
Royal Oak, Michigan, United States
Corewell Health Lakeland Hospitals - Saint Joseph Hospital
Saint Joseph, Michigan, United States
Corewell Health Beaumont Troy Hospital
Troy, Michigan, United States
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, United States
Saint Luke's Hospital of Duluth
Duluth, Minnesota, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, United States
Regions Hospital
Saint Paul, Minnesota, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
North Kansas City Hospital
Kansas City, Missouri, United States
University of Kansas Cancer Center - North
Kansas City, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Billings Clinic Cancer Center
Billings, Montana, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Renown Regional Medical Center
Reno, Nevada, United States
Saint Mary's Regional Medical Center
Reno, Nevada, United States
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Capital Health Medical Center-Hopewell
Pennington, New Jersey, United States
ProCure Proton Therapy Center-Somerset
Somerset, New Jersey, United States
Virtua Voorhees
Voorhees Township, New Jersey, United States
New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York, United States
Memorial Sloan Kettering Commack
Commack, New York, United States
Memorial Sloan Kettering Westchester
Harrison, New York, United States
Northwell Health/Center for Advanced Medicine
Lake Success, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Montefiore Medical Center - Moses Campus
The Bronx, New York, United States
Mission Hospital
Asheville, North Carolina, United States
Novant Health Forsyth Medical Center
Winston-Salem, North Carolina, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Sanford Bismarck Medical Center
Bismarck, North Dakota, United States
Sanford Roger Maris Cancer Center
Fargo, North Dakota, United States
Cleveland Clinic Akron General
Akron, Ohio, United States
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, United States
Geauga Hospital
Chardon, Ohio, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, United States
Case Western Reserve University
Cleveland, Ohio, United States
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Riverside Methodist Hospital
Columbus, Ohio, United States
Mercy Cancer Center-Elyria
Elyria, Ohio, United States
Cleveland Clinic Cancer Center Independence
Independence, Ohio, United States
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, United States
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, United States
UH Seidman Cancer Center at Southwest General Hospital
Middleburg Heights, Ohio, United States
University Hospitals Parma Medical Center
Parma, Ohio, United States
North Coast Cancer Care
Sandusky, Ohio, United States
UH Seidman Cancer Center at Firelands Regional Medical Center
Sandusky, Ohio, United States
Cleveland Clinic Cancer Center Strongsville
Strongsville, Ohio, United States
University of Toledo
Toledo, Ohio, United States
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, United States
UHHS-Westlake Medical Center
Westlake, Ohio, United States
Cleveland Clinic Wooster Family Health and Surgery Center
Wooster, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Willamette Valley Cancer Center
Eugene, Oregon, United States
Legacy Mount Hood Medical Center
Gresham, Oregon, United States
Legacy Good Samaritan Hospital and Medical Center
Portland, Oregon, United States
Saint Luke's University Hospital-Bethlehem Campus
Bethlehem, Pennsylvania, United States
Northeast Radiation Oncology Center
Dunmore, Pennsylvania, United States
Ephrata Cancer Center
Ephrata, Pennsylvania, United States
Adams Cancer Center
Gettysburg, Pennsylvania, United States
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania, United States
Sechler Family Cancer Center
Lebanon, Pennsylvania, United States
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Jefferson Torresdale Hospital
Philadelphia, Pennsylvania, United States
Reading Hospital
West Reading, Pennsylvania, United States
WellSpan Health-York Cancer Center
York, Pennsylvania, United States
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, United States
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, United States
Self Regional Healthcare
Greenwood, South Carolina, United States
Prisma Health Cancer Institute - Greer
Greer, South Carolina, United States
Prisma Health Cancer Institute - Seneca
Seneca, South Carolina, United States
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, United States
Tennessee Cancer Specialists-Dowell Springs
Knoxville, Tennessee, United States
Dell Seton Medical Center at The University of Texas
Austin, Texas, United States
Austin Cancer Centers-Central Austin
Austin, Texas, United States
Texas Oncology-Austin Midtown
Austin, Texas, United States
Texas Oncology - Central Austin Cancer Center
Austin, Texas, United States
Texas Oncology - South Austin Cancer Center
Austin, Texas, United States
Austin Cancer Centers-North
Austin, Texas, United States
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, United States
Texas Oncology - Denison Cancer Center
Denison, Texas, United States
Texas Oncology-Flower Mound
Flower Mound, Texas, United States
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, United States
University of Texas Medical Branch
Galveston, Texas, United States
Memorial Hermann Memorial City Medical Center
Houston, Texas, United States
M D Anderson Cancer Center
Houston, Texas, United States
UTMB Cancer Center at Victory Lakes
League City, Texas, United States
Covenant Medical Center-Lakeside
Lubbock, Texas, United States
Texas Oncology-Seton Williamson
Round Rock, Texas, United States
Texas Oncology - Round Rock Cancer Center
Round Rock, Texas, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Texas Oncology Cancer Center Sugar Land
Sugar Land, Texas, United States
Texas Oncology - Tyler
Tyler, Texas, United States
Logan Regional Hospital
Logan, Utah, United States
Intermountain Medical Center
Murray, Utah, United States
McKay-Dee Hospital Center
Ogden, Utah, United States
Utah Valley Regional Medical Center
Provo, Utah, United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States
Saint George Regional Medical Center
St. George, Utah, United States
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont, United States
University of Vermont Medical Center
Burlington, Vermont, United States
Dartmouth Cancer Center - North
Saint Johnsbury, Vermont, United States
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, United States
FHCC at Northwest Hospital
Seattle, Washington, United States
FHCC Proton Therapy Center
Seattle, Washington, United States
University of Washington Medical Center - Montlake
Seattle, Washington, United States
Compass Oncology Vancouver
Vancouver, Washington, United States
Legacy Salmon Creek Hospital
Vancouver, Washington, United States
Wheeling Hospital/Schiffler Cancer Center
Wheeling, West Virginia, United States
Langlade Hospital and Cancer Center
Antigo, Wisconsin, United States
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, United States
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
UW Cancer Center at ProHealth Care
Waukesha, Wisconsin, United States
Aspirus Regional Cancer Center
Wausau, Wisconsin, United States
BCCA-Vancouver Island Cancer Centre
Victoria, British Columbia, Canada
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, Canada
Windsor Regional Cancer Centre
Windsor, Ontario, Canada
CHUM - Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
The Research Institute of the McGill University Health Centre (MUHC)
Montreal, Quebec, Canada
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Québec, Quebec, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCT02163135
Identifier Type: -
Identifier Source: nct_alias
NCI-2014-01072
Identifier Type: REGISTRY
Identifier Source: secondary_id
NRG-BN001
Identifier Type: OTHER
Identifier Source: secondary_id
NRG-BN001
Identifier Type: OTHER
Identifier Source: secondary_id
NRG-BN001
Identifier Type: -
Identifier Source: org_study_id